A systematic review of the outcomes reported in the treatment of uncomplicated urinary tract infection clinical trials.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
21
07
2021
accepted:
18
02
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Uncomplicated urinary tract infections (UTIs) are amongst the most frequent infections presenting in the outpatient setting. A growing number of clinical trials are assessing the most effective treatment interventions for uncomplicated UTI. Due to the heterogeneity of the outcomes reported in these trials, however, comparing these outcomes is challenging. Identify the core outcomes that have been reported in trials and systematic reviews of interventions treating uncomplicated UTI in adults. We conducted a systematic search for core outcomes used to evaluate treatments of UTIs. We searched the Cochrane Database of Systematic Reviews, PubMed and Embase. One researcher independently screened each article for inclusion, and the Core Outcome Set for treatment of Urinary Tract Infections (COSUTI) team acted as second reviewers. All included articles were screened by two reviewers. All outcomes were extracted verbatim, and similar outcomes were grouped into domains and subdomains. In total, 334 outcomes were reported across 41 papers, the average number of outcomes reported being 8. Outcomes were categorized across 18 domains, the majority of which were related to clinical cure outcomes. Many outcomes varied in the timepoints within which the outcome was measured and reported. Comparing the outcomes of trials investigating uncomplicated UTI treatment remains challenging due to the difference in outcomes currently reported. Consistency of reporting of outcomes would be improved by developing a minimum number of consistent outcomes that should be reported in all trials.
Sections du résumé
Background
UNASSIGNED
Uncomplicated urinary tract infections (UTIs) are amongst the most frequent infections presenting in the outpatient setting. A growing number of clinical trials are assessing the most effective treatment interventions for uncomplicated UTI. Due to the heterogeneity of the outcomes reported in these trials, however, comparing these outcomes is challenging.
Objectives
UNASSIGNED
Identify the core outcomes that have been reported in trials and systematic reviews of interventions treating uncomplicated UTI in adults.
Methods
UNASSIGNED
We conducted a systematic search for core outcomes used to evaluate treatments of UTIs. We searched the Cochrane Database of Systematic Reviews, PubMed and Embase. One researcher independently screened each article for inclusion, and the Core Outcome Set for treatment of Urinary Tract Infections (COSUTI) team acted as second reviewers. All included articles were screened by two reviewers. All outcomes were extracted verbatim, and similar outcomes were grouped into domains and subdomains.
Results
UNASSIGNED
In total, 334 outcomes were reported across 41 papers, the average number of outcomes reported being 8. Outcomes were categorized across 18 domains, the majority of which were related to clinical cure outcomes. Many outcomes varied in the timepoints within which the outcome was measured and reported.
Conclusions
UNASSIGNED
Comparing the outcomes of trials investigating uncomplicated UTI treatment remains challenging due to the difference in outcomes currently reported. Consistency of reporting of outcomes would be improved by developing a minimum number of consistent outcomes that should be reported in all trials.
Identifiants
pubmed: 35350132
doi: 10.1093/jacamr/dlac025
pii: dlac025
pmc: PMC8944192
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
dlac025Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Int J Antimicrob Agents. 2011 Dec;38 Suppl:21-35
pubmed: 22000072
Infect Dis Clin North Am. 1997 Sep;11(3):551-81
pubmed: 9378923
J Antimicrob Chemother. 2010 Sep;65(9):1862-77
pubmed: 20587612
Arch Intern Med. 2007 Nov 12;167(20):2207-12
pubmed: 17998493
Fam Pract. 2012 Dec;29(6):659-70
pubmed: 22516128
Actas Urol Esp. 2013 Mar;37(3):147-55
pubmed: 22995326
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Ann Epidemiol. 2000 Nov;10(8):509-15
pubmed: 11118930
Clin Microbiol Infect. 2017 Jun;23(6):363-372
pubmed: 27956267
BMC Infect Dis. 2016 Dec 1;16(1):727
pubmed: 27905884
J Antimicrob Chemother. 2015 Sep;70(9):2456-64
pubmed: 26066581
Cochrane Database Syst Rev. 2016 Apr 19;4:CD010745
pubmed: 27090883
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Res Rep Urol. 2017 Mar 14;9:43-50
pubmed: 28352615
BMJ. 2017 Nov 7;359:j4784
pubmed: 29113968
BMJ. 2010 Feb 05;340:c199
pubmed: 20139214
BMC Infect Dis. 2012 Jun 28;12:146
pubmed: 22742538
Scand J Prim Health Care. 2009;27(1):6-11
pubmed: 18991182
J Antimicrob Chemother. 2007 Aug;60(2):247-57
pubmed: 17562680
JAMA. 2012 Feb 8;307(6):583-9
pubmed: 22318279
J Infect. 2009 Feb;58(2):91-102
pubmed: 19195714
Cochrane Database Syst Rev. 2010 Oct 06;(10):CD007182
pubmed: 20927755
Int Sch Res Notices. 2014 Nov 02;2014:906843
pubmed: 27437504
Sultan Qaboos Univ Med J. 2013 Aug;13(3):359-67
pubmed: 23984019
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Infect Dis Clin North Am. 2009 Jun;23(2):355-85; Table of Contents
pubmed: 19393914
Chemotherapy. 2012;58(3):249-56
pubmed: 22890091
Br J Gen Pract. 2018 Apr;68(669):e268-e278
pubmed: 29483078
BMJ. 2015 Dec 23;351:h6544
pubmed: 26698878
Trials. 2007 Nov 26;8:39
pubmed: 18039365
BMC Infect Dis. 2014 Dec 17;14:693
pubmed: 25516016
Trials. 2013 Mar 22;14:84
pubmed: 23522152
Gac Med Mex. 2015 Mar-Apr;151(2):225-44
pubmed: 25946534
Scand J Prim Health Care. 2007 Mar;25(1):49-57
pubmed: 17354160
Int J Antimicrob Agents. 2008 Feb;31(2):130-4
pubmed: 18060746
J Health Serv Res Policy. 2012 Jan;17(1):1-2
pubmed: 22294719
Trials. 2017 Sep 8;18(1):421
pubmed: 28886751
J Antimicrob Chemother. 2014 Jun;69(6):1675-80
pubmed: 24508899
Infez Med. 2015 Jun;23(2):155-60
pubmed: 26110296
Fam Pract. 2017 Sep 1;34(5):511-519
pubmed: 28486675
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001535
pubmed: 18646074
J Infect Chemother. 2010 Dec;16(6):424-30
pubmed: 20585969
BMC Med. 2010 May 26;8:30
pubmed: 20504298
Trials. 2019 Feb 7;20(1):106
pubmed: 30732617
J Ayub Med Coll Abbottabad. 2016 Oct-Dec;28(4):734-737
pubmed: 28586607
JAMA. 2014 Oct 22-29;312(16):1677-84
pubmed: 25335150
Dtsch Arztebl Int. 2011 Jun;108(24):415-23
pubmed: 21776311
Urology. 2016 Apr;90:50-5
pubmed: 26825489
Int J Infect Dis. 2017 May;58:96-109
pubmed: 28341436
J Antimicrob Chemother. 2017 Feb;72(2):529-534
pubmed: 27733519
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120